Your browser doesn't support javascript.
loading
Next-generation CRISPR technology for genome, epigenome and mitochondrial editing.
Lau, Cia-Hin; Liang, Qing-Le; Zhu, Haibao.
Afiliação
  • Lau CH; Department of Biology, College of Science, Shantou University, Shantou, 515063, Guangdong, China.
  • Liang QL; Department of Clinical Laboratory Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.
  • Zhu H; Department of Biology, College of Science, Shantou University, Shantou, 515063, Guangdong, China. zhuhaibao@stu.edu.cn.
Transgenic Res ; 2024 Aug 19.
Article em En | MEDLINE | ID: mdl-39158822
ABSTRACT
The application of rapidly growing CRISPR toolboxes and methods has great potential to transform biomedical research. Here, we provide a snapshot of up-to-date CRISPR toolboxes, then critically discuss the promises and hurdles associated with CRISPR-based nuclear genome editing, epigenome editing, and mitochondrial editing. The technical challenges and key solutions to realize epigenome editing in vivo, in vivo base editing and prime editing, mitochondrial editing in complex tissues and animals, and CRISPR-associated transposases and integrases in targeted genomic integration of very large DNA payloads are discussed. Lastly, we discuss the latest situation of the CRISPR/Cas9 clinical trials and provide perspectives on CRISPR-based gene therapy. Apart from technical shortcomings, ethical and societal considerations for CRISPR applications in human therapeutics and research are extensively highlighted.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article